{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:53:05Z","timestamp":1792057985041,"version":"4.4.0"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"27","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,9,20]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Epidermal growth factor receptor\/human epidermal growth factor receptor 1 (EGFR\/HER1) and ligand expression is frequently seen in hepatocellular cancers (HCCs). Erlotinib (Tarceva, OSI-774; OSI Pharmaceuticals, Melville, NY) is a receptor tyrosine kinase inhibitor with specificity for the EGFR\/HER1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The primary objective of this study was to determine the proportion of patients with advanced HCC who were progression-free at 6 months. Patients with either unresectable or metastatic disease were studied. Only one prior systemic or locoregional therapy was allowed. Erlotinib was given continuously at a dose of 150 mg per day orally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-eight patients with HCC were enrolled. Median age of the patients was 69 years (range, 27 to 83 years). A majority of patients (63%) had an Eastern Cooperative Oncology Group performance status of 1. Forty-seven percent of patients had received prior chemotherapy for advanced HCC. EGFR\/HER1 expression was detected in 88% of the patients. Median number of cycles per patient was two (range, 1 to 26). Twelve (32%; CI 95%, 18 to 49) of the 38 patients with HCC were progression-free at 6 months. Three patients had partial radiologic responses of duration of 2, 10, and 11 months, respectively. Disease control was seen in 59% of the patients. Median overall survival time was 13 months. Ten patients (26%) had toxicity-related dose reductions of erlotinib. Grade 3\/4 skin toxicity or diarrhea was encountered in five and three patients, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Results of this trial suggest a benefit for EGFR\/HER1 blockade with erlotinib in patients with HCC manifested by disease control. Additional studies with erlotinib as a single agent or in combination with other agents are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2005.14.696","type":"journal-article","created":{"date-parts":[[2005,9,16]],"date-time":"2005-09-16T22:02:59Z","timestamp":1126908179000},"page":"6657-6663","source":"Crossref","is-referenced-by-count":374,"title":["Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer"],"prefix":"10.1200","volume":"23","author":[{"given":"Philip A.","family":"Philip","sequence":"first","affiliation":[{"name":"From the Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Johns Hopkins University, Baltimore, MD; Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Scottsdale, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; and Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Mahoney","sequence":"additional","affiliation":[{"name":"From the Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Johns Hopkins University, Baltimore, MD; Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Scottsdale, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; and Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristine","family":"Allmer","sequence":"additional","affiliation":[{"name":"From the Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Johns Hopkins University, Baltimore, MD; Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Scottsdale, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; and Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Thomas","sequence":"additional","affiliation":[{"name":"From the Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Johns Hopkins University, Baltimore, MD; Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Scottsdale, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; and Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry C.","family":"Pitot","sequence":"additional","affiliation":[{"name":"From the Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Johns Hopkins University, Baltimore, MD; Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Scottsdale, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; and Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kim","sequence":"additional","affiliation":[{"name":"From the Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Johns Hopkins University, Baltimore, MD; Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Scottsdale, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; and Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross C.","family":"Donehower","sequence":"additional","affiliation":[{"name":"From the Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Johns Hopkins University, Baltimore, MD; Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Scottsdale, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; and Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Fitch","sequence":"additional","affiliation":[{"name":"From the Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Johns Hopkins University, Baltimore, MD; Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Scottsdale, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; and Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Picus","sequence":"additional","affiliation":[{"name":"From the Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Johns Hopkins University, Baltimore, MD; Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Scottsdale, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; and Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Erlichman","sequence":"additional","affiliation":[{"name":"From the Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Johns Hopkins University, Baltimore, MD; Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Scottsdale, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; and Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401001"},{"key":"R2","unstructured":"Ihde DC, Kane RC, Cohen MH, et al: Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 61:1385,1977-1387,"},{"key":"R3","unstructured":"Chlebowski RT, Brzechwa Adjukiewicz A, Cowden A, et al: Doxorubicin (75 mg\/m) for hepatocellular carcinoma: Clinical and pharmacokinetic results. Cancer Treat Rep 68:487,1984-491,\n                      2"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851215)56:12<2751::AID-CNCR2820561205>3.0.CO;2-O"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(77)80024-8"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(88)90066-7"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90707-2"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(98)00045-X"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9084"},{"key":"R11","unstructured":"Kaneko Y, Shibuya M, Nakayama T, et al: Hypomethylation of c-myc and epidermal growth factor receptor genes in human hepatocellular carcinoma and fetal liver. Jpn J Cancer Res 76:1136,1985-1140,"},{"key":"R12","unstructured":"Xu YH, Jiang WL, Peng SF: EGFR\/HER1 expression and EGF stimulation of proliferation in human liver carcinoma cells [in Chinese]. Shi Yan Sheng Wu Xue Bao 22:445,1989-453,"},{"key":"R13","unstructured":"Hung WC, Chuang LY, Tsai JH, et al: Effects of epidermal growth factor on growth control and signal transduction pathways in different human hepatoma cell lines. Biochem Mol Biol Int 30:319,1993-328,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930580409"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(95)90275-9"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.2307\/2531951"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Cox DR: Regression models and life tables (with discussion). J R Stat Soc (B) 74:187,1972-220,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Lenz HJ, Mayer RJ, Gold PJ, et al: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. J Clin Oncol 23:248,2004,  (abstr 3510)","DOI":"10.1200\/jco.2004.22.90140.3510"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Philip PA, Mahoney M, Thomas J, et al: Phase II trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer. J Clin Oncol 23:318, 2004 (abstr 4025)","DOI":"10.1200\/jco.2004.22.90140.4025"},{"key":"R23","unstructured":"Tanaka H: Immunohistochemical studies on epidermal growth factor receptor in hepatocellular carcinoma. [in Japanese]. Nippon Shokakibyo Gakkai Zasshi 88:138,1991-144,"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00043-4"},{"key":"R25","unstructured":"Sirotnak FM, Zakowsky MF, Miller VA, et al: Potentiation of cytotoxic agents against human tumors in mice by ZD1839 (IRESSA), an inhibitor of EGFR\/HER1 tyrosine kinase, does not require high levels of expression of EGFR\/HER1. Proc Annu Meet Am Assoc Cancer Res 41:482,2000,  (abstr 3076)"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204372"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib. N Engl J Med, Volume: 350:2129,2004-2139,","DOI":"10.1056\/NEJMoa040938"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.14.696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T16:45:09Z","timestamp":1653497109000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.14.696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,20]]},"references-count":27,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2005,9,20]]}},"alternative-id":["10.1200\/JCO.2005.14.696"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.14.696","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,20]]}}}